Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan;10(1):314–325. doi: 10.21037/tlcr-20-549

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Clinical outcome of RET rearranged NSCLC patients treated with alectinib. (A) Swimmer plot of all patients treated with alectinib. Bars indicate duration of alectinib treatment. The response [partial response (PD), stable disease (SD) and progressive disease (PD)] in 34 patients (9 in phase 1 and 25 in phase 2) was assessed by central review (RECIST v1.1). The fusion partner for RET in each patient is shown on the left side of the bars. Arrows indicate patients who were previously treated with other RET-TKIs. (B) Spider plot of all patients treated with alectinib. RET, rearranged during transfection; NSCLC, non-small cell lung cancer.